Change in longest diameter = -19%. Change in sum of perpendicular diameters = -21%

Slides:

Advertisements

Similar presentations

Accenture Life Sciences Rethink Reshape Restructure… for better patient outcomes CDISC Journey in Lymphoma using Cheson 2007 Kevin Lee CDISC NJ meeting.

Advertisements

Hani A. Nabi, M.D., Ph.D. Department of Nuclear Medicine School of Medicine and Biomedical Science University at Buffalo State University of New York Buffalo,

Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors J Clin Oncol Jan 20;24(3): Vs 劉俊煌 CR 周益聖財團法人台灣癌症臨床研究發展基金會.

The Need for Quantitative Imaging in Oncology Richard L. Schilsky, M.D. Professor of Medicine, Associate Dean for Clinical Research, University of Chicago.

Introduction to PET/CT in Oncology: Practical Aspects Jeffrey T. Yap, PhD Department of Imaging Dana-Farber Cancer Institute.

Response Assessment Criteria for Clinical Trials Tumor Imaging Metrics Core January 29, 2008 Cheryl A. Sadow, MD Abdominal Imaging & Intervention Division.

Total Lesion Glycolysis by 18 F-FDG PET/CT a Reliable Predictor of Prognosis in Soft Tissue Sarcoma Ilkyu Han Musculoskeletal Tumor Center, Seoul National.

Response Evaluation of Gastrointestinal Stromal Tumors (GIST)

ISSSMA June 3 rd Advanced quantification in oncology PET Irène Buvat IMNC – UMR 8165 CNRS – Paris 11 University Orsay, France

Tumor Measurement Criteria milestones & 2000

-1- 3DSlicer Quantitative Medical Imaging Session: Quick Overview and PET/CT Analysis Jeffrey Yap, Ph.D. Ron Kikinis, M.D. Randy Gollub, M.D., Ph.D Wendy.

PET in Colorectal Cancer. Indications for FDG PET Rising marker, (-) CT/MRI Nonspecific findings on CT/MRI, recurrence or post treatment changes? Known.

May 19-20, Quantitation, both single point and longitudinal*, of tumor metabolism via FDG-PET/CT that can be used practically and efficiently as.

Jeffrey Yap, PhD Ron Kikinis, MD Wendy Plesniak, PhD -1- CTSA at RSNA 2009 PET/CT Analysis using 3D Slicer Jeffrey Yap PhD Ron Kikinis MD Wendy Plesniak.

COMBI RECIST 1.1 February Target Lesions: Selection at Baseline Perform baseline evaluations as close to treatment start as possible (no more than.

RECIST Overview.

Immune Related Response Criteria (irRC) Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors Training Presentation v3.0.

Anatomic and Functional Imaging Evaluation of a Clinical Trial of an IGFR Antibody in Patients (PTS) with Ewing Sarcoma (ES) Vadim Koshkin; Vanessa Bolejack;

PET/CT Analysis using 3D Slicer Jeffrey Yap PhD Ron Kikinis MD Wendy Plesniak PhD Slicer3 Training Compendium.

Implementation of Oncology specific SDTM domains

EORTC Tumor response to pre-operative chemotherapy (CT) with FOLFOX-4 for resectable colorectal cancer liver metastases (LM) Interim results of the EORTC.

Supplemental Figure S1: Representative sections showing changes in expression between baseline biopsy and post-treatment surgical specimens BaselinePost.

Albert J. Chang, MD, PhD 1 Farrokh Dehdashti, MD 2 Perry W. Grigsby, MD, MS 1 Department of Radiation Oncology 1 Department of Radiology and Nuclear Medicine.

In my clinical practice I use FDG-PET for the following 1- Staging 2- Therapeutic monitoring 3- Staging and therapeutic monitoring 4- I do not use FDG-PET;

Monday Case of the Day A) The treatment was successful: The bremsstrahlung SPECT (Fig 2) indicates that 90 Y was deposited in the tumor. B) The treatment.

The Optimization of Reconstruction Method Reducing Partial Volume Effect in PET/CT 3D Image Acquisition Department of Nuclear Medicine, Samsung Medical.

간담도 암에서의 PET 의 활용 핵의학과 홍일기. 18 F-FDG PET: Warburg effect.

University of Pennsylvania Department of Orthopaedic Surgery Joseph King, Eileen Crawford, Abass Alavi, Arthur Staddon, Lee Hartner, Richard Lackman and.

Fig. 9. Warthin's tumor, a 72-year-old man with supraglottic cancer. A

Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel Makoto Kawaishi, MD, Yutaka Fujiwara, MD,

Volume 164, Issue 6, Pages (December 2000)

PET Criteria for Response Assessment After Completion of Therapy for Aggressive NHL and HL Definition of a positive PET scan (Visual assessment is adequate,

A phase I pharmacokinetic and pharmacodynamic study of weekly MK-0646, an Insulin Like Growth Factor-1 Receptor (IGF-1R) monoclonal antibody in patients.

Korde N et al. Proc ASH 2012;Abstract 732.

A case report of locally advanced triple negative breast cancer showing pathological complete response to weekly paclitaxel with bevacizumab treatment.

Accenture Life Sciences

Simultaneous positron emission tomography (PET) assessment of metabolism with 18F- fluoro-2-deoxy-d-glucose (FDG), proliferation with 18F-fluoro-thymidine.

Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related.

Realistic Lenalidomide Dose Adjustment Strategy for Transplant-Ineligible Elderly Patients with Relapsed/Refractory Multiple Myeloma: Japanese Real-World.

How I treat extramedullary myeloma

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria M. Tazdait,

Volume 65, Issue 4, Pages (April 2014)

Clinical and Translational Radiation Oncology

Early Response to Platinum-Based First-Line Chemotherapy in Non-small Cell Lung Cancer May Predict Survival Bhawna Sirohi, MBBS, DCH, Sue Ashley, BSc,

Volume 18, Issue 4, Pages (April 2010)

Phosphoglyceride crystal deposition disease mimicking a malignant tumor Hiroyuki Tokue, Masayuki Ebara, Ryosuke Takahashi, Azusa Tokue, Yoshito Tsushima

Waterfall plot of the best per cent change from baseline in SLD of target lesions in 33 patients. Waterfall plot of the best per cent change from baseline.

Response to Carfilzomib Therapy

Metabolic response by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT). a) FDG PET/CT for patient 2 at baseline.

Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal.

Preliminary Report of Late Recurrences, at 5 Years or More, after Stereotactic Body Radiation Therapy for Non-small Cell Lung Cancer Yukinori Matsuo,

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer Johan F. Vansteenkiste, MD, PhD, Jean-Luc.

Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer Charles M. Rudin, MD, PhD,

(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.

Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non–Small-Cell Lung Cancer after.

A Pilot Study of Preoperative Gefitinib for Early-Stage Lung Cancer to Assess Intratumor Drug Concentration and Pathways Mediating Primary Resistance

Circulating Endothelial Cells in Non-small Cell Lung Cancer Patients Treated with Carboplatin and Paclitaxel Makoto Kawaishi, MD, Yutaka Fujiwara, MD,

Fig F-FGln shows uptake in human gliomas undergoing progression.

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction.

Linear correlationa between TMB cutoff for ORb for CR/PR rates and HRc for PFS, and OS depending on TMB for patients treated with anti-PD-1/PD-L1 monotherapy.

Noninvasive detection of acquired MET amplification as a mechanism of afatinib/trastuzumab resistance using cfDNA. Noninvasive detection of acquired MET.

Fig. 2. SUVmax on PET-CT and associated characteristics

Lack of FDG Uptake in Small Cell Carcinoma Associated with ANNA-1 Positive Paraneoplastic Autonomic Neuropathy Matthew S. Block, MD, PhD, Robert Vassallo,

Correlation of PTEN loss in melanoma cells with an immune resistance phenotype. Correlation of PTEN loss in melanoma cells with an immune resistance phenotype.

Individual treatment outcomes of 20 patients treated with afatinib and 12 patients treated with afatinib and trastuzumab. Individual treatment outcomes.

(A) Survival curves according to clinical response.

Hyun-Sung Lee, MD, PhD, Cynthia Y. Truong, BS, Bryan M. Burt, MD

Survival, subsequent therapies, and response.

Figure 12a Pitfalls in N staging at CT and PET

Presentation transcript:

Change in longest diameter = -19%

Change in sum of perpendicular diameters = -21%

Change in CT Volume = -37%

Change in PET SUVmax = -18%

Comparison of Response Measures Change in longest diameter = -19% Change in sum of perpendicular diameters = -21% Change in CT Volume = -37% Change in PET SUVmax = -18%

Standardized Uptake Value Under certain circumstances, 18 FDG SUV correlates with metabolic rate of glucose and/or the number of viable tumor cells Simplified semi-quantitative measure that can be routinely performed in clinical PET studies Adjusts for differences in patient size and injected activity SUV (time) = Radioactive Concentration x Weight Injected Activity

EORTC PET metabolic response criteria Complete response (CR): Complete resolution of all lesions Partial Response (PR): Greater than or equal to 25% decrease in SUVmax. Stable Disease (SD): Less than 25% change Progressive Disease (PD): Greater than or equal to 25% increase in SUVmax